S. Danner

发表

Faster Identification of Pathogens in Positive Blood Cultures by Fluorescence In Situ Hybridization in Routine Practice

P. Savelkoul, C. Vandenbroucke-Grauls, R. Peters, 2006, Journal of Clinical Microbiology.

Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy.

N M Ferguson, A. Ghani, C. Donnelly, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group.

C. Dreezen, G. Weverling, S. Danner, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Adherence over 48 Weeks in An Antiretroviral Clinical Trial: Variable within Patients, Affected by Toxicities and Independently Predictive of Virological Response

S. Danner, P. Nieuwkerk, E. Gisolf, 2000, Antiviral therapy.

Failure to maintain high-dose treatment regimens during long-term use of zidovudine in patients with symptomatic human immunodeficiency virus type 1 infection.

P. Reiss, S. Danner, P. van den Hurk, 1990, Genitourinary medicine.

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals

P. Reiss, J. Beijnen, F. Wit, 2000, AIDS.

Mycobacterium xenopi in HIV‐infected patients: an emerging pathogen

E. Kuijper, P. Speelman, S. Danner, 1998, AIDS.

Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents.

P. Reiss, M. D. de Jong, S. Danner, 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

QUOTE-HIV: an instrument for assessing quality of HIV care from the patients’ perspective

J. V. D. van der Meer, S. Danner, P. Bindels, 2003, Quality & safety in health care.

Echocardiographic dimensions and maximal oxygen uptake in oarsmen during training.

A. J. Dunning, S. Danner, W. Wieling, 1981, British heart journal.

T-cell progenitor function during progressive human immunodeficiency virus-1 infection and after antiretroviral therapy.

P. Reiss, F. Wit, S. Repping, 2000, Blood.

Effects of protease inhibitors on the course of CMV retinitis in relation to CD4+ lymphocyte responses in HIV+ patients

P. Reiss, S. Danner, G. J. van den Horn, 1998, The British journal of ophthalmology.

Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis.

H. Schuitemaker, P. Reiss, I. Keet, 1999, The Journal of infectious diseases.

Prevalence and determinants for malnutrition in geriatric outpatients.

O. J. de Vries, S. Danner, M. Kramer, 2013, Clinical nutrition.

Effect of physical exercise on blood lipids and adipose tissue composition in young healthy men.

A. J. Dunning, L. Havekes, S. Danner, 1984, Atherosclerosis.

Cytomegalovirus retinitis in AIDS patients: a comparative study of intravenous and oral ganciclovir as maintenance therapy.

S. Danner, S. Matheron, 1996, AIDS.

Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection

P. Reiss, F. Wit, M. van der Valk, 2001, AIDS.

Impact of diarrhoea and faecal incontinence on the daily life of HIV-infected patients.

B. Steenbergen, J. D. de Boer, F. V. van Dam, 1998, AIDS care.

Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.

H. Schuitemaker, P. Reiss, C. Boucher, 1997, The Journal of clinical investigation.

T cell expansions in lymph nodes and peripheral blood in HIV-1-infected individuals: effect of antiretroviral therapy

S. Kostense, P. Reiss, S. Danner, 2001, AIDS.

The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a Phase I study

S. Danner, J. Lange, E. Hussey, 1992, AIDS.

Detection of bacterial DNA in blood samples from febrile patients: underestimated infection or emerging contamination?

P. Savelkoul, C. Vandenbroucke-Grauls, R. Peters, 2004, FEMS immunology and medical microbiology.

Quantitative Detection of Staphylococcus aureus and Enterococcus faecalis DNA in Blood To Diagnose Bacteremia in Patients in the Intensive Care Unit

P. Savelkoul, C. Vandenbroucke-Grauls, R. Peters, 2007, Journal of Clinical Microbiology.

UvA-DARE ( Digital Academic Repository ) CMV retinitis in HIV-positive patients in the pre-HAART era

Marcel, F. Verbraak, M. Bruinenberg, 2012 .

Autoimmunity against blood cells in human immunodeficiency-virus (HIV) infection

S. Danner, J. Lange, C. Dalen, 1987 .

Failure of zidovudine prophylaxis after accidental exposure to HIV-1.

P. Reiss, C. Boucher, C. Hollak, 1990, The New England journal of medicine.

The Lopinavir/Ritonavir-Associated Rise in Lipids is not Related to Lopinavir or Ritonavir Plasma Concentration

P. Reiss, W. Bierman, S. Danner, 2011, Antiviral therapy.

Prediction of infarct size from serial CK determinations: evaluation by clinical studies and computer simulation.

A. J. Dunning, S. Danner, H. Oosting, 1979, Clinica chimica acta; international journal of clinical chemistry.

Effects of recombinant human granulocyte colony‐stimulating factor on leucopenia in zidovudine‐treated patients with AIDS and AIDS related complex, a phase I/II study

R. V. van Oers, S. Danner, J. Lange, 1991, British journal of haematology.

Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA

F. Villarroya, P. Reiss, F. Wit, 2012, AIDS.

First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir

P. Lips, P. Reiss, S. Geerlings, 2009, AIDS.

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review

C. Boucher, W. Bierman, S. Danner, 2009, AIDS.

[HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].

P. Reiss, G. Weverling, F. de Wolf, 2001, Nederlands tijdschrift voor geneeskunde.

Macronodular adrenocortical hyperplasia in a postmenopausal woman.

S. Danner, G. S. Mijnhout, F. V. D. van de Goot, 2004, The Netherlands journal of medicine.

Conversion rate towards a syncytium inducing (SI) phenotype during different stages of HIV infection and prognostic value of SI phenotype for survival after aids diagnoses

H. Schuitemaker, I. Keet, S. Danner, 1997 .

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

P. Reiss, F. Wit, S. Danner, 2000, AIDS.

Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection.

M. Zupancic, A. Haase, R. Mills, 1997, Science.

Zidovudine/Lamivudine for HIV-1 Infection Contributes to Limb Fat Loss

P. Reiss, S. Geerlings, A. Milinkovic, 2009, PloS one.

Cutting Edge: Rapid Recovery of NKT Cells upon Institution of Highly Active Antiretroviral Therapy for HIV-1 Infection1

P. Reiss, S. Danner, M. V. van Agtmael, 2006, The Journal of Immunology.

Antiretroviral Therapy for HIV-1 Infection upon Institution of Highly Active Cutting Edge: Rapid Recovery of NKT Cells

P. Reiss, M. Agtmael, S. Danner, 2006 .

Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells.

D. Richman, S. Little, Steven Wolinsky, 1999, Science.

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

J. Sninsky, C. Loveday, C. Boucher, 1995, The Journal of infectious diseases.

[Generalized histoplasmosis in 3 patients with an HIV infection].

E. Kuijper, S. Danner, R. Heyligenberg, 1990, Nederlands tijdschrift voor geneeskunde.

Management of cytomegalovirus disease.

S. Danner, 1995, AIDS.

Invasive external otitis caused by Aspergillus fumigatus in two patients with AIDS.

P. Reiss, S. Danner, L. Schot, 1991, AIDS.

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.

L. M. Lehman, J. Leonard, A. Hsu, 1995, The New England journal of medicine.

Prevalence of Campylobacter-associated diarrhea among patients infected with human immunodeficiency virus.

E. Kuijper, L. van der Hoek, J. Dankert, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Diarrhoea in HIV‐infected patients: no evidence of cytokine‐mediated inflammation in jejunal mucosa

P. Reiss, J. Bartelsman, S. V. van Deventer, 1995, AIDS.

Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.

J. Goudsmit, F. de Wolf, S. Danner, 1986, British medical journal.

Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus.

J. Goudsmit, S. Danner, L. Verdonck, 1986, British medical journal.

Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs.

Jaap, F. Miedema, A. J. Petit, 1988, The Journal of clinical investigation.

Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases

N. Foudraine, S. Danner, K. Brinkman, 2000, International journal of STD & AIDS.

Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections.

D. Richman, B. Gazzard, C. Katlama, 1998, Antiviral research.

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients : A randomized controlled comparison with zidovudine monotherapy

P. Harrigan, S. Staszewski, M. Johnson, 1996 .

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

P. Harrigan, S. Staszewski, C. Loveday, 1996, JAMA.

Results of long-term follow-up of HIV-infected patients treated with lamivudine monotherapy, followed by a combination of lamivudine and zidovudine.

P. Reiss, C. Boucher, S. Danner, 1997, Antiviral Therapy.

Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine

P. Portegies, F. de Wolf, S. Danner, 2000, AIDS.

Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy

P. Reiss, H. Yki-Jărvinen, H. Sauerwein, 2008, AIDS.

The duration of viral suppression during protease inhibitor therapy for HIV‐1 infection is predicted by plasma HIV‐1 RNA at the nadir

J. Leonard, A. Molla, C. Boucher, 1998, AIDS.

The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine

M. Borst, F. de Wolf, S. Danner, 2000, AIDS.

Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons.

P. Reiss, F. Wit, G. Weverling, 1999, The Journal of infectious diseases.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation

Rob J. De Boer, John M. Leonard, Frank De Wolf, 1998, Nature Medicine.

Low Incidence of Anti-Interferon-Alpha Antibodies in Patients Treated with Interferon-Alpha-2A for AIDS-Associated Kaposi's Sarcoma

R. de Wit, S. Danner, P. Bakker, 1990, International journal of STD & AIDS.

Mortality in Patients With Successful Initial Response to Highly Active Antiretroviral Therapy Is Still Higher Than in Non-HIV-Infected Individuals

A. Ghani, R. Anderson, F. de Wolf, 2005, Journal of acquired immune deficiency syndromes.

Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy.

N. Foudraine, S. Danner, M. Klein, 1999, The Journal of infectious diseases.

Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.

Tom de Groot, C. Boucher, S. Danner, 1997, The Journal of infectious diseases.

Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection

S. Danner, J. Lange, P. Nieuwkerk, 2001, AIDS.

Post-exposure prophylaxis

J. V. D. van der Meer, S. Danner, G. Schreij, 2002, International journal of STD & AIDS.

Alternative multidrug regimen provides improved suppression of HIV‐1 replication over triple therapy

H. Schuitemaker, G. Weverling, F. de Wolf, 1998, AIDS.

Viral Replication Under Combination Antiretroviral Therapy: A Comparison of Four Different Regimens

C. Fraser, A. Ghani, C. Donnelly, 2002, Journal of acquired immune deficiency syndromes.

Increasing Cerebrospinal Fluid Chemokine Concentrations Despite Undetectable Cerebrospinal Fluid HIV RNA in HIV‐1‐Infected Patients Receiving Antiretroviral Therapy

P. Portegies, S. Danner, S. Jurriaans, 2000, Journal of acquired immune deficiency syndromes.

Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy.

P. Portegies, J. Goudsmit, S. Danner, 2000 .

Implantation of cultured thymic fragments in patients with acquired immunodeficiency syndrome.

S. Danner, H. Schuurman, J. Lange, 1986, Archives of internal medicine.

Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations.

D. Mcclernon, J. Goudsmit, F. de Wolf, 2000, AIDS research and human retroviruses.

Rate of HIV‐1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen

A S Perelson, A. Perelson, J. Mittler, 1998, AIDS.

New developments in the diagnosis of bloodstream infections.

P. Savelkoul, C. Vandenbroucke-Grauls, R. Peters, 2004, The Lancet. Infectious diseases.

Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy.

A S Perelson, W S Hlavacek, A. Perelson, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Declining incidence of AIDS dementia complex after introduction of zidovudine treatment.

P. Portegies, H. Speelman, J. Goudsmit, 1989, BMJ.

Antigen-specific T-lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV-1 infection.

S. Danner, M. Klein, N. Pakker, 1999, Immunology Letters.

UvA-DARE (Digital Academic Repository) Functional T cell reconstruction and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy

N. Foudraine, S. Danner, M. Klein, 1999 .

Biochemical and circulatory parameters during purely mental stress.

A. J. Dunning, R. Koster, S. Danner, 2009, Acta medica Scandinavica.

Diversity of the T‐cell receptor BV repertoire in HIV‐1‐infected patients reflects the biphasic CD4+ T‐cell repopulation kinetics during highly active antiretroviral therapy

S. Kostense, S. Danner, J. Teale, 1998, AIDS.

Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.

M. Sprangers, M. Chesney, F. de Wolf, 2001, Archives of internal medicine.

Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV‐2‐infected patients

A. Osterhaus, J. Veenstra, H. Niesters, 2003, AIDS.

Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline.

J. Goudsmit, F. de Wolf, S. Danner, 1987, AIDS.

Pathogenesis of HIV and its implications for serodiagnosis and monitoring of antiviral therapy.

L. Epstein, J. Goudsmit, S. Danner, 1987, Journal of virological methods.

Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses.

J. Goudsmit, S. Danner, J. Cremers, 2001, AIDS research and human retroviruses.

Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines.

W. Bierman, G. Jansen, S. Danner, 2010, The Journal of antimicrobial chemotherapy.

Increased numbers of granzyme-B-expressing cytotoxic T-lymphocytes in the small intestine of HIV-infected patients.

S. Danner, P. Wever, C. Hack, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection.

D. Richman, H. Günthard, S. Little, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection.

M. Zupancic, A. Haase, R. Mills, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Additive or sequential nucleoside analogue therapy compared with continued zidovudine monotherapy in human immunodeficiency virus-infected patients with advanced disease does not prolong survival: an observational study.

G. Bonsel, P. Reiss, S. Danner, 1997, The Journal of infectious diseases.

Attitudes of health-care workers towards AIDS at three Dutch hospitals.

S. Danner, H. Sno, J. Storosum, 1991, AIDS.

Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs.

R. D. de Boer, J. Goudsmit, S. Danner, 2001, AIDS research and human retroviruses.

Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs.

M. Hillebrand, J. Goudsmit, F. de Wolf, 1999, AIDS.

Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults.

N. Foudraine, J. Goudsmit, S. Danner, 1999, The Journal of infectious diseases.

Rapid Identification of Pathogens in Blood Cultures with a Modified Fluorescence In Situ Hybridization Assay

C. Vandenbroucke-Grauls, R. Peters, A. Simoons-Smit, 2006, Journal of Clinical Microbiology.

The MEDICLAS study (Metabolic Effects of Different Classes of AntiretroviralS)

P. Reiss, S. Danner, 2003 .

Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy

A. Wu, M. Sprangers, S. Danner, 2000, AIDS.

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection Marieke den Brinker a , Ferdinand W. N. M. Wit a ,

P. Reiss, G. Weverling, S. Danner, 2000 .

Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy.

P. Reiss, C. Stehouwer, S. Danner, 2009, The Journal of infectious diseases.

Low antigenicity of HIV-1 rev: rev-specific antibody response of limited value as correlate of rev gene expression and disease progression.

C. Debouck, P. Reiss, J. Goudsmit, 1989, AIDS research and human retroviruses.

Insulin Sensitivity in Multiple Pathways Is Differently Affected During Zidovudine/Lamivudine-Containing Compared With NRTI-Sparing Combination Antiretroviral Therapy

P. Reiss, H. Yki-Jărvinen, H. Sauerwein, 2010, Journal of acquired immune deficiency syndromes.

Carotid Intima-Media Thickness and Arterial Stiffness in HIV-Infected Patients: The Role of HIV, Antiretroviral Therapy, and Lipodystrophy

C. Gundy, P. Reiss, M. Agtmael, 2009, Journal of acquired immune deficiency syndromes.

Multifactorial intervention to reduce falls in older people at high risk of recurrent falls: a randomized controlled trial.

D. Knol, L. Bouter, P. Lips, 2010, Archives of internal medicine.

Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use

Benjamin J Cowling, Christl A Donnelly, Roy M Anderson, 2006, AIDS.

Common health problems in HIV-infected travelers to the (sub)tropics.

F. Cobelens, S. Danner, F. Cobelens, 1999, Journal of travel medicine.

TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen

G. Weverling, S. Danner, S. Jurriaans, 2003, AIDS.

Persistence of human immunodeficiency virus antigenemia in patients with the acquired immunodeficiency syndrome treated with a reverse transcriptase inhibitor, suramin. Ten-patient case-control study.

J. Goudsmit, S. Danner, J. Lange, 1988, Archives of internal medicine.

HIV infection and squamous cell carcinoma of sun-exposed skin.

S. Danner, W. A. de Boer, 1990, AIDS.

A Dose-Ranging Study to Evaluate the Antiretroviral Activity and Safety of Amprenavir Alone and in Combination with Abacavir in HIV-Infected Adults with Limited Antiretroviral Experience

R. Schooley, R. Haubrich, F. Antunes, 2000, Antiviral Therapy.

[CBO guidelines 'Antiretroviral therapy in the Netherlands'].

S. Danner, J. Borleffs, J. V. van Everdingen, 2001, Nederlands tijdschrift voor geneeskunde.

Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir

S. Danner, R. Hoetelmans, E. Gisolf, 2000, AIDS.

Cardiovascular health in the tenth decade.

A. J. Dunning, S. Danner, M. de Beaumont, 1978, British medical journal.

High-dose interferon-alpha2a exerts potent activity against human immunodeficiency virus type 1 not associated with antitumor activity in subjects with Kaposi's sarcoma.

P. Reiss, J. Goudsmit, F. de Wolf, 1997, The Journal of infectious diseases.

Antigen-driven CD 4 1 T cell and HIV-1 dynamics : Residual viral replication under highly active antiretroviral therapy

C. Fraser, A. Ghani, C. Donnelly, 1999 .

Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine.

J. Goudsmit, F. de Wolf, S. Danner, 1988, AIDS.

Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.

R. Tubiana, C. Katlama, C. Boucher, 1995, The Journal of infectious diseases.

Evaluation of sorivudine (BV-araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus-infected adults. The Multinational Sorivudine Study Group.

W. Rozenbaum, A. Rachlis, S. Danner, 1997, The Journal of infectious diseases.

Safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitor

D. Ho, J. Leonard, A. Hsu, 1995, Antimicrobial agents and chemotherapy.

Therapy for cytomegalovirus polyradieulomyelitis in patients with AIDS: treatment with ganciclovir

D. Troost, P. Portegies, S. Danner, 1990, AIDS.

Increasing Cerebrospinal Fluid Chemokine Concentrations Despite Undetectable Cerebrospinal Fluid HIV RNA in HIV‐1‐Infected Patients Receiving Antiretroviral Therapy

P. Portegies, S. Danner, S. Jurriaans, 2000, Journal of acquired immune deficiency syndromes.

Post-exposure prophylaxis

J. V. D. van der Meer, S. Danner, R. M. Regez, 2002, International journal of STD & AIDS.

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review

C. Boucher, W. Bierman, S. Danner, 2009, AIDS.

Transcellular activation of the human immunodeficiency virus type 1 long terminal repeat in cocultured lymphocytes

C. V. Noesel, F. Miedema, K. Tung, 1992, Journal of virology.

G. Bonsel, P. Reiss, S. Danner, 1997, The Journal of infectious diseases.

Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy.

P. Reiss, C. Stehouwer, S. Danner, 2009, The Journal of infectious diseases.

Studies on the efficacy and toxicity of highly active antiretroviral therapy

P. Reiss, G. Weverling, S. Danner, 2007 .